Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
企業コードBDSX
会社名Biodesix Inc
上場日Oct 28, 2020
最高経営責任者「CEO」Mr. Scott Hutton
従業員数273
証券種類Ordinary Share
決算期末Oct 28
本社所在地919 West Dillon Road
都市LOUISVILLE
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号80027
電話番号13034170500
ウェブサイトhttps://www.biodesix.com/
企業コードBDSX
上場日Oct 28, 2020
最高経営責任者「CEO」Mr. Scott Hutton
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし